Overview
Please join us for a discussion and Q&A with Dr. Shana Kelley (Kelley Laboratory), a tenured professor and director at the University of Toronto with 20+ years’ experience in clinical/molecular diagnostics. Hedgeye Health Care sector head Tom Tobin and Dr. Kelley will discuss the innovation cycle and transition to practice from theory, including the evolution of liquid biopsy (cf/ctDNA and circulating tumor cells), the significance of DeepMind’s AI and protein folding (we think it’s a really big deal!), advancements in single cell and spatial sequencing (TXG & NSTG), and what's next for point-of-care diagnostics!
With liquid biopsy gaining traction for treatment selection and disease monitoring, how far off is a reliable pan-cancer test? Illumina (ILMN) and Exact (EXAS) placed large bets on Grail and Thrive, respectively, so where does that leave Guardant, Foundation, Natera, et al.? What are the practical limits of theory in diagnostics (i.e., how far off are we - consumers - from being able to quickly, cheaply, and reliably test for cancer or infectious diseases at home)? Join us to find out!
|
Health Care Speaker Call | Where Theory Meets Practice Please join us on TODAY @ 10 AM ET - Add to Outlook Calendar CLICK HERE for event details (includes video and materials link). |
Speaker Bio
Dr. Shana Kelley is a Distinguished Professor of Biochemistry, Pharmaceutical Sciences, Chemistry, and Biomedical Engineering at the University of Toronto. She received her Ph.D. from the California Institute of Technology and was a NIH postdoctoral fellow at the Scripps Research Institute. Her research interests are the development of new technologies for clinical diagnostics and drug delivery. Dr. Kelley’s work has been recognized with a variety of distinctions, including being named one of ‘Canada’s Top 40 under 40′, a NSERC E.W.R. Steacie Fellow, and the 2011 Steacie Prize, among others. She is an inventor on over 50 patents issued worldwide and a founder of three molecular diagnostics companies: GeneOhm Sciences (acquired by Becton Dickinson in 2005), Xagenic Inc. (acquired by General Atomics in 2017), and Cellular Analytics.
Sample of Recent Publications:
“Detection of SARS-CoV-2 Viral Particles using Direct, Reagent-Free Electrochemical Sensing.”
H. Yousefi, A. Mahmud, D. Chang, J. Das, S. Gomis, J.B. Chen, H. Wang, T. Been, L.Yip, E. Coomes, Z. Li, S. Mubareka, A. McGeer, N. Christie, S. Gray-Owen, A. Cochrane, J.M. Rini, E.H. Sargent, S.O. Kelley
Chemxriv, 2020, doi.org/10.26434/chemrxiv.13103561.v1. link
“Reagentless Biomolecular Analysis Using a Nanoscale Molecular Pendulum.”
J. Das, S. Gomis, J.B. Chen, H. Yousefi, S.Ahmed, A. Mahmud, W. Zhou, E. H. Sargent, S.O. Kelley
Bioxriv, 2020, doi: 10.1101/2020.04.02.020453v1. link
“Tracking the Expression of Therapeutic Protein Targets in Rare Cells by Antibody-Mediated Nanoparticle Labelling and Magnetic Sorting.”
M. Labib, Z. Wang, S.U. Ahmed, R.M. Mohamadi, B. Duong, B. Green, E.H. Sargent
Nature Biomedical Engineering, 2020, doi: 10.1038/s41551-020-0590-1. link
“Fluorescent Droplet Cytometry for On-Cell Phenotype Tracking.”
X. Yang, W. liu, D. C.-H. Chan, S.U. Ahmed, H. Wang, Z. Wang, C.R. Nemr, S.O. Kelley
Journal of the American Chemical Society, 2020, 142, 14805–14809. link
“A Multiplexed, Electrochemical Interface for Gene Circuit-Based Sensors.”
P. Sadat Mousavi, S.J. Smith, J.B. Chen, M. Karlikow, A. Tinafar, W. Liu, D. Ma, A.A. Green, S.O. Kelley,* K. Pardee*
Nature Chemistry, 2020, 12, 48-55. link
“A New Era in Liquid Biopsy: From Genotype to Phenotype.” S.O. Kelley and K. Pantel,
Clinical Chemistry, 2020, 66, 89-96. link
Please send us your questions for Dr. Kelley via .
We hope you can join us!
Thomas Tobin
Managing Director
Twitter
LinkedIn
